Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 7/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 7/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3714075 | 0.90 | EPHX2 (0.48) | EPHX2KMT2APOLBCASP3FABP5 | |
| SCHEMBL30001282 | 0.89 | EPHX2 (0.47) | EPHX2MAPK8MAPK9MAPK10KMT2A | |
| SCHEMBL23412767 | 0.89 | EPHX2 (0.47) | EPHX2MAPK8MAPK9MAPK10KMT2A | |
| SCHEMBL29446051 | 0.89 | EPHX2 (0.47) | EPHX2KMT2APOLBCASP3FABP5 | |
| SCHEMBL19260383 | 0.89 | EPHX2 (0.47) | EPHX2KMT2APOLBCASP3FABP5 | |
| SCHEMBL30000091 | 0.82 | FABP5 (0.47) | EPHX2KMT2ACASP3FABP5PTPN1 | |
| SCHEMBL23413466 | 0.82 | FABP5 (0.47) | EPHX2KMT2ACASP3FABP5PTPN1 | |
| SCHEMBL21247379 | 0.81 | EPHX2 (0.41) | EPHX2KMT2APOLBCASP3FABP5 | |
| SCHEMBL21247413 | 0.80 | CNR2 (0.40) | EPHX2MAPK8MAPK9MAPK10KMT2A | |
| SCHEMBL30300681 | 0.78 | EPHX2 (0.45) | EPHX2KMT2ACASP3FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767316-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767316-B2 | Non-fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | EPHX2 3705/4885MAPK8 4188/4885MAPK9 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.